Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Qiagen N : to Launch Easy-to-Use Digital Test in the U.S. for Rapid Detection of SARS-CoV-2 Antibodies Following FDA Emergency Use Authorization

share with twitter share with LinkedIn share with facebook
08/24/2020 | 05:03pm EDT

  • Access Anti-SARS-CoV-2 is an easy-to-use 10-minute test on a portable device that provides highly accurate results on Total Ig antibodies (IgA, IgM, IgG)
  • New test based on QIAGEN partner Ellume’s proprietary technology, addresses current test shortfalls in terms of automation and convenient read-out of results
  • Digital eHub and eStick system provides rapid qualitative serological in-vitro detection of total antibodies to SARS-CoV-2 in plasma and serum
  • U.S. launch set to start in late August 2020 after submission for FDA Emergency Use Authorization, European CE-IVD marking and commercialization start planned in coming weeks

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of the new Access Anti-SARS-CoV-2 Total test, an easy-to-use digital test done on a portable device that provides results in about 10 minutes to detect antibodies in people exposed to the SARS-CoV-2 virus, which is the case of COVID-19.

The launch of this antibody test, which was developed in partnership with the Australian digital diagnostics company Ellume, comes after the submission by QIAGEN of this unique antibody test to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA). First shipments are planned for late August 2020. A CE-IVD marking for Europe and other markets is planned in the coming weeks.

The new serological test has been shown to have sensitivity of 100% (CI 88.43–100.00%) and specificity of 100% (CI 95.20–100.00%).

The test is performed on the eHub, a small portable digital device that provides reliable results in 10 minutes. Each eHub can handle up to eight patient samples simultaneously and can perform up to 32 total tests per hour. The nanoparticle fluorescent detection technology uses serum or plasma from patient samples. The same platform is being used for QuantiFERON-TB Access, a new solution in development for diagnosis of latent tuberculosis (TB) infection in low-resource regions with a high TB disease burden.

Please find the full press release here.

Further information on QIAGEN’s response to the coronavirus outbreak can be found here.

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about QIAGEN N.V.
10/29QIAGEN N : expands its existing Epigenomic offering in the United States with Sa..
PU
10/28QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
10/28QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
10/28QIAGEN NV : JP Morgan maintains a Buy rating
MD
10/28QIAGEN N : launches QIAseq Human Exome TR Insights, a new integrated solution fo..
PU
10/28QIAGEN NV : Jefferies reiterates its Neutral rating
MD
10/27QIAGEN : 3Q Earnings Snapshot
AQ
10/27QIAGEN N.V. : to hold investor call on Wednesday, October 28, after releasing re..
BU
10/27QIAGEN N : Ad hoc Announcement according to Art. 17 Market Abuse Regulation
PU
10/27QIAGEN N : reports strong results for third quarter and first nine months of 202..
PU
More news
Financials (USD)
Sales 2020 1 814 M - -
Net income 2020 277 M - -
Net Debt 2020 996 M - -
P/E ratio 2020 41,8x
Yield 2020 -
Capitalization 10 888 M 10 888 M -
EV / Sales 2020 6,55x
EV / Sales 2021 5,64x
Nbr of Employees 5 300
Free-Float 92,9%
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 55,82 $
Last Close Price 47,60 $
Spread / Highest target 38,7%
Spread / Average Target 17,3%
Spread / Lowest Target -20,2%
EPS Revisions
Managers
NameTitle
Thierry Bernard Chief Executive Officer
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.40.83%10 888
LONZA GROUP AG56.63%44 852
SEAGEN INC.68.34%33 467
CELLTRION, INC.39.78%29 849
IQVIA HOLDINGS INC.0.09%29 650
MODERNA, INC.264.42%28 126